Research graph
References from The use of locoregional therapies in cholangiocarcinoma. Local targets link to admitted publications; unresolved targets remain external evidence.
Anatomical, histomorphological and molecular classification of cholangiocarcinoma
10.1111/liv.14093 · 2019 · External reference
Prognostic factors for patients with mass-forming intrahepatic cholangiocarcinoma: a case series of 68 patients
10.4240/wjgs.v14.i5.442 · 2022 · External reference
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
10.1038/s41575-020-0310-z · 2020 · External reference
Cholangiocarcinoma 2026: status quo, unmet needs and priorities
10.1038/s41575-025-01153-w · 2026 · External reference
Unresolved reference
External reference
Epidemiology, survival and new treatment modalities for intrahepatic cholangiocarcinoma
10.21037/jgo-24-165 · 2024 · External reference
Surgery for cholangiocarcinoma
10.1111/liv.14089 · 2019 · External reference
Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study
10.1016/j.jhep.2025.05.003 · 2025 · External reference
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blnd, placebo-controlled, phase 3 trial
10.1016/s0140-6736(23)00727-4 · 2023 · External reference
Local therapy reduces the risk of liver failure and improves survival in patients with intrahepatic cholangiocarcinoma: a comprehensive analysis of 362 consecutive patients
10.1002/cncr.30488 · 2017 · External reference
The influence of hepatic steatosis and fibrosis on postoperative outcomes after major liver resection of perihilar cholangiocarcinoma
10.1245/s10434-023-14419-x · 2024 · External reference
Primary percutaneous stenting for palliative biliary drainage of patients with malignant hilar biliary obstruction: TESLA trial
2025 · External reference
Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma: a retrospective dose response analysis
10.1200/jco.2015.61.3778 · 2016 · External reference
Stereotactic body radiation therapy after chemotherapy for unresectable perihilar cholangiocarcinoma: the STRONG trial, a phase I safety and feasibility study
10.3390/cancers13163991 · 2021 · External reference
Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial
10.1001/jamaoncol.2019.3702 · 2020 · External reference
Hepatic arterial infusion pump chemotherapy in patients with unresectable intrahepatic cholangiocarcinoma-PUMP-2 trial
2025 · External reference
Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
10.1016/j.annonc.2022.10.506 · 2023 · External reference
BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update
10.1016/j.jhep.2025.10.020 · 2026 · External reference
Radiofrequency ablation and microwave ablation in liver tumors: an update
10.1634/theoncologist.2018-0337 · 2019 · External reference
Combination of intraoperative radiofrequency ablation and surgical resection for treatment of cholangiocarcinoma: feasibility and long-term survival
10.5152/dir.2019.18552 · 2020 · External reference
Clinical and survival outcomes of percutaneous microwave ablation for intrahepatic cholangiocarcinoma
10.1080/02656736.2017.1327678 · 2018 · External reference
Extensive use of interventional therapies improves survival in unresectable or recurrent intrahepatic cholangiocarcinoma
10.1155/2016/8732521 · 2016 · External reference
EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma
10.1016/j.jhep.2023.03.010 · 2023 · External reference
The blood supply of experimental liver metastases. IV. Changes in vascularity with increasing tumor growth
1974 · External reference
The blood supply of neoplasms in the liver
1954 · External reference
Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival
10.1093/annonc/mdp029 · 2009 · External reference
Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results?
10.1159/000324704 · 2011 · External reference
Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: a phase 2 clinical trial
10.1001/jamaoncol.2019.3718 · 2020 · External reference
Interventionally implanted port catheter systems for hepatic arterial infusion of chemotherapy in patients with colorectal liver metastases: a Phase II-study and historical comparison with the surgical approach
10.1186/1471-2407-7-69 · 2007 · External reference
Comparison of hepatic arterial infusion chemotherapy with mFOLFOX vs. first-line systemic chemotherapy in patients with unresectable intrahepatic cholangiocarcinoma
10.3389/fphar.2023.1234342 · 2023 · External reference
Potential efficacy of hepatic arterial infusion chemotherapy using gemcitabine, cisplatin, and 5-fluorouracil for intrahepatic cholangiocarcinoma
10.1371/journal.pone.0266707 · 2022 · External reference
Thermal ablation in the treatment of intrahepatic cholangiocarcinoma: a systematic review and meta-analysis
10.1007/s00330-021-08216-x · 2022 · External reference
Radiofrequency ablation for intrahepatic cholangiocarcinoma: retrospective analysis of a single centre experience
2011 · External reference
Treatment of intrahepatic cholangiocarcinoma: evidence for the role of percutaneous ablation
2023 · External reference
Ablation of intrahepatic cholangiocarcinoma
10.1055/s-0039-1696649 · 2019 · External reference
Thermal ablation versus surgical resection of small-size colorectal liver metastases (COLLISION): an international, randomised, controlled, phase 3 non-inferiority trial
10.1016/s1470-2045(24)00660-0 · 2025 · External reference
Cryoablation plus sintilimab and lenvatinib in advanced or metastatic intrahepatic cholangiocarcinoma: a phase 2 trial
10.1038/s43018-025-01058-2 · 2026 · External reference
Interventional treatment strategies in intrahepatic cholangiocarcinoma and perspectives for combined hepatocellular-cholangiocarcinoma
10.3390/cancers15092655 · 2023 · External reference
Percutaneous irreversible electroporation (IRE) of hepatic malignancy: a Bi-institutional analysis of safety and outcomes
10.1007/s00270-018-2120-z · 2019 · External reference
Cholangiocarcinoma: CT-guided high-dose rate brachytherapy (CT-HDRBT) for limited (<4 cm) and large (>4 cm) tumors
10.21873/anticanres.12926 · 2018 · External reference
Computed tomography-guided interstitial HDR brachytherapy (CT-HDRBT) of the liver in patients with irresectable intrahepatic cholangiocarcinoma
10.1007/s00270-011-0249-0 · 2012 · External reference
Addition of stereotactic body radiotherapy (SBRT) to systemic chemotherapy in locally advanced cholangiocarcinoma (CC)(ABC-07): results from a randomized phase II trial
10.1200/jco.2024.42.16_suppl.4006 · 2024 · External reference
Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Federation Francophone de Cancerologie Digestive 9902 phase II randomised study
10.1016/j.ejca.2014.08.013 · 2014 · External reference
Stereotactic body radiotherapy for primary hepatic malignancies - report of a phase I/II institutional study
10.1016/j.radonc.2016.07.020 · 2016 · External reference
Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma
10.1200/jco.2007.14.3529 · 2008 · External reference
Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma
10.1200/jco.2015.64.2710 · 2016 · External reference
Ablative liver radiotherapy for unresected intrahepatic cholangiocarcinoma: patterns of care and survival in the United States
10.1002/cncr.34223 · 2022 · External reference
Transarterial chemoembolization and radioembolization for unresectable intrahepatic cholangiocarcinoma-a systemic review and meta-analysis
10.1007/s00270-021-02800-w · 2021 · External reference
Transarterial chemoembolization (TACE) for inoperable intrahepatic cholangiocarcinoma
10.1007/s00270-007-9032-7 · 2007 · External reference
Comparison of resection and transarterial chemoembolisation in the treatment of advanced intrahepatic cholangiocarcinoma--a single-center experience
10.1016/j.ejso.2013.03.010 · 2013 · External reference
Comparison of the efficacy and safety among apatinib plus drug-eluting bead transarterial chemoembolization (TACE), apatinib plus conventional TACE and apatinib alone in advanced intrahepatic cholangiocarcinoma
2020 · External reference
Combination of TACE and Lenvatinib as a promising option for downstaging to surgery of initially unresectable intrahepatic cholangiocarcinoma
10.1007/s10637-022-01257-z · 2022 · External reference
10.1186/s12957-025-03679-4
10.1186/s12957-025-03679-4 · 2025 · External reference
Chemotherapy with or without selective internal radiation therapy for intrahepatic cholangiocarcinoma: data from clinical trials
10.1097/hep.0000000000000544 · 2024 · External reference
Radioembolization with yttrium-90 glass microspheres as a first-line treatment for unresectable intrahepatic cholangiocarcinoma-A prospective feasibility study
10.1016/j.jvir.2023.05.026 · 2023 · External reference
Selective internal radiation therapy with yttrium-90 resin microspheres followed by gemcitabine plus cisplatin for unresectable intrahepatic cholangiocarcinoma: a phase 2 single-arm multicenter clinical trial
10.1159/000525489 · 2022 · External reference
Survival after transarterial radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: an updated meta-analysis and meta-regression
10.1007/s00270-024-03825-7 · 2024 · External reference
Unresolved reference
2017 · External reference
Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial
10.1016/s2468-1253(20)30290-9 · 2021 · External reference
Tumor absorbed dose predicts survival and local tumor control in colorectal liver metastases treated with 90Y radioembolization
10.1007/s00270-025-04175-8 · 2026 · External reference
Liver function after combined selective internal radiation therapy or sorafenib monotherapy in advanced hepatocellular carcinoma
10.1016/j.jhep.2021.07.037 · 2021 · External reference
Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study
10.1002/hep.31819 · 2021 · External reference
Radiation segmentectomy and modified radiation lobectomy for unresectable early-stage intrahepatic cholangiocarcinoma
10.1016/j.jvir.2024.12.016 · 2025 · External reference
Feasibility of radioembolization with yttrium-90 resin microspheres without lung shunt fraction measurement for intrahepatic cholangiocarcinoma
10.3348/kjr.2025.1558 · 2026 · External reference
10.1159/000551430
10.1159/000551430 · External reference
Unresolved reference
2021 · External reference
Unresolved reference
2024 · External reference
Hepatic arterial infusion of gemcitabine plus oxaliplatin as second-line treatment for locally advanced intrahepatic cholangiocarcinoma: preliminary experience
10.1159/000362223 · 2013 · External reference
Efficacy analysis of HAIC combined with lenvatinib plus PD1 inhibitor vs. first-line systemic chemotherapy for advanced intrahepatic cholangiocarcinoma
2024 · External reference
Hepatic arterial infusion of GEMOX plus systemic gemcitabine chemotherapy combined with lenvatinib and PD-1 inhibitor in large unresectable intrahepatic cholangiocarcinoma
10.1016/j.intimp.2024.112872 · 2024 · External reference
A comparative study of clinicopathological and imaging features of HBV-negative and HBV-positive intrahepatic cholangiocarcinoma patients with different pathologic differentiation degrees
10.1038/s41598-023-47108-6 · 2023 · External reference
10.1016/j.jhep.2026.06.022
10.1016/j.jhep.2026.06.022 · External reference
STRONG II trial: stereotactic body radiation therapy following chemotherapy for unresectable perihilar cholangiocarcinoma - a single-arm multicentre phase II study
10.1136/bmjopen-2024-097545 · 2025 · External reference
Adjuvant chemoradiation and immunotherapy for extrahepatic cholangiocarcinoma and gallbladder cancer: a randomized clinical trial
10.1001/jamaoncol.2025.1926 · 2025 · External reference
Swog S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma
10.1200/jco.2014.60.2219 · 2015 · External reference
Liver transplantation as a new standard of care in patients with perihilar cholangiocarcinoma? Results from an international benchmark study
10.1097/sla.0000000000005641 · 2022 · External reference
Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma
10.1034/j.1600-6143.2002.20812.x · 2002 · External reference
Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma
10.1053/lv.2000.6143 · 2000 · External reference
Surgery for cholangiocarcinoma: the role of liver transplantation
10.1080/13651820801992542 · 2008 · External reference
Liver transplantation for cholangiocarcinoma
10.1111/j.1432-2277.2010.01108.x · 2010 · External reference
Liver transplantation for peri-hilar cholangiocarcinoma
10.1007/s11605-020-04721-4 · 2020 · External reference
Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers
10.1053/j.gastro.2012.04.008 · 2012 · External reference
Outcomes of irreversible electroporation for perihilar cholangiocarcinoma: a prospective pilot study
10.1016/j.jvir.2022.03.024 · 2022 · External reference
EASL Clinical Practice Guidelines on the management of extrahepatic cholangiocarcinoma
10.1016/j.jhep.2025.03.007 · 2025 · External reference
Nationwide treatment and outcomes of perihilar cholangiocarcinoma
10.1111/liv.14856 · 2021 · External reference
Protocol for a phase iii randomized trial of chemoradiation and systemic chemotherapy vs. systemic chemotherapy alone in patients with unresectable nonmetastatic cholangiocarcinoma
10.18203/2349-3259.ijct20170303 · 2017 · External reference
